DK2179035T3 - Modificeret bakteriofag omfattende et alfa/beta-sasp-(small acid-soluble spore protein)-gen - Google Patents

Modificeret bakteriofag omfattende et alfa/beta-sasp-(small acid-soluble spore protein)-gen

Info

Publication number
DK2179035T3
DK2179035T3 DK08786965.7T DK08786965T DK2179035T3 DK 2179035 T3 DK2179035 T3 DK 2179035T3 DK 08786965 T DK08786965 T DK 08786965T DK 2179035 T3 DK2179035 T3 DK 2179035T3
Authority
DK
Denmark
Prior art keywords
bacteriophagic
sasp
alfa
beta
gene
Prior art date
Application number
DK08786965.7T
Other languages
English (en)
Inventor
Heather Fairhead
Adam Wilkinson
Sarah Holme
Katy Pitts
Alison Jackson
Original Assignee
Phico Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phico Therapeutics Ltd filed Critical Phico Therapeutics Ltd
Application granted granted Critical
Publication of DK2179035T3 publication Critical patent/DK2179035T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/00041—Use of virus, viral particle or viral elements as a vector
    • C12N2795/00043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
DK08786965.7T 2007-08-07 2008-08-06 Modificeret bakteriofag omfattende et alfa/beta-sasp-(small acid-soluble spore protein)-gen DK2179035T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0715416.4A GB0715416D0 (en) 2007-08-07 2007-08-07 Modified bacteriophage
PCT/EP2008/060360 WO2009019293A1 (en) 2007-08-07 2008-08-06 Modified bacteriophage including an alpha/beta small acid-soluble spore protein (sasp) gene

Publications (1)

Publication Number Publication Date
DK2179035T3 true DK2179035T3 (da) 2013-04-08

Family

ID=38543208

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08786965.7T DK2179035T3 (da) 2007-08-07 2008-08-06 Modificeret bakteriofag omfattende et alfa/beta-sasp-(small acid-soluble spore protein)-gen

Country Status (13)

Country Link
US (4) US8697049B2 (da)
EP (1) EP2179035B8 (da)
JP (3) JP5582354B2 (da)
AU (1) AU2008285659B2 (da)
CA (1) CA2695939C (da)
DK (1) DK2179035T3 (da)
ES (1) ES2402176T3 (da)
GB (2) GB0715416D0 (da)
HR (1) HRP20130250T1 (da)
PL (1) PL2179035T3 (da)
PT (1) PT2179035E (da)
SI (1) SI2179035T1 (da)
WO (1) WO2009019293A1 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0715416D0 (en) 2007-08-07 2007-09-19 Phico Therapeutics Ltd Modified bacteriophage
GB201417810D0 (en) 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modifying bacteriophage
GB201417808D0 (en) * 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modified bacteriophage
GB201417805D0 (en) 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modifield bacteriophage
GB201417811D0 (en) * 2014-10-08 2014-11-19 Phico Therapeutics Ltd Modifying bacteriophage
AU2015362618B2 (en) * 2014-12-16 2022-01-27 C3J Therapeutics, Inc. Compositions of and methods for in vitro viral genome engineering
GB2544956A (en) * 2015-07-08 2017-06-07 Phico Therapeutics Ltd Polypeptides, polynucleotides and uses thereof
GB201600075D0 (en) * 2016-01-03 2016-02-17 Glaxosmithkline Biolog Sa Immunogenci composition
US10736928B2 (en) 2016-01-20 2020-08-11 Richard Brian Murphy, JR. Pegylated recombinant bacteriophage
CA3020375A1 (en) 2016-04-08 2017-10-12 Phico Therapeutics Ltd Modified bacteriophage
WO2017174809A1 (en) * 2016-04-08 2017-10-12 Phico Therapeutics Ltd Modifying bacteriophage
WO2019140534A1 (en) * 2018-01-19 2019-07-25 Cytophage Technologies Inc. Genetically engineered bacteriophage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0028130D0 (en) * 2000-11-17 2001-01-03 Phico Therapeutics Ltd Polypeptide and uses thereof
GB0314469D0 (en) * 2003-06-20 2003-07-23 Phico Therapeutics Ltd Antimicrobial compositions and uses thereof
DE102004061846A1 (de) * 2004-12-22 2006-07-13 Basf Ag Mehrfachpromotoren
EP2796544B1 (en) * 2005-09-09 2019-04-03 Duke University Tissue engineering methods and compositions
GB0715416D0 (en) 2007-08-07 2007-09-19 Phico Therapeutics Ltd Modified bacteriophage

Also Published As

Publication number Publication date
US10106784B2 (en) 2018-10-23
AU2008285659B2 (en) 2013-09-19
US11559560B2 (en) 2023-01-24
PL2179035T3 (pl) 2013-08-30
JP5582354B2 (ja) 2014-09-03
GB2451750B (en) 2010-06-02
ES2402176T3 (es) 2013-04-29
CA2695939A1 (en) 2009-02-12
JP2014221038A (ja) 2014-11-27
JP2016144444A (ja) 2016-08-12
CA2695939C (en) 2013-11-19
GB0814385D0 (en) 2008-09-10
GB0715416D0 (en) 2007-09-19
SI2179035T1 (sl) 2013-05-31
WO2009019293A1 (en) 2009-02-12
EP2179035B8 (en) 2013-04-03
AU2008285659A1 (en) 2009-02-12
US8697049B2 (en) 2014-04-15
US20100239536A1 (en) 2010-09-23
US20190071648A1 (en) 2019-03-07
US20140242032A1 (en) 2014-08-28
US20160319244A1 (en) 2016-11-03
EP2179035A1 (en) 2010-04-28
PT2179035E (pt) 2013-04-04
JP2010535482A (ja) 2010-11-25
JP6177357B2 (ja) 2017-08-09
GB2451750A (en) 2009-02-11
EP2179035B1 (en) 2013-02-27
HRP20130250T1 (hr) 2013-04-30
US9359596B2 (en) 2016-06-07

Similar Documents

Publication Publication Date Title
LTPA2018015I1 (lt) Genų inžinerijos būdu pagaminti anti-IL-23P19 antikūnai
DK2046826T3 (da) Exendin-fusionsproteiner
EP1982167A4 (en) BIOSENSOR
DK3118220T3 (da) Protein
DK2129781T3 (da) Hafnia-phytase
EP2172198A4 (en) P27 PROTEIN INDUKTOR
EP2220247A4 (en) ANTIBODY AGAINST LRP6
BRPI0814971A2 (pt) Proteína
DE102007013391A8 (de) Zeitinformationsquelle
EP2212435A4 (en) FUSIONED GENE BZW. FUSIONED GENES
PL2140269T3 (pl) Podpis białkowy/znaczniki do wykrywania gruczolakoraka
EP2011880A4 (en) Taurine-GEN
EP2129285A4 (en) Analyte sensor
SI2179035T1 (sl) Modificiran bakteriofag, ki vključuje gen alfa/beta majhnega, v kislini topnega sporinega proteina (SASP)
DK2152108T3 (da) Fodtøjsemne
BRPI0812489A2 (pt) Genes que codificam proteínas inseticidas
BRPI0814310A2 (pt) Enzima lecitina-colesterol acetiltransferase modificada
FI20065652A0 (fi) Jallkine
EP2192402A4 (en) Enzyme electrode
ATE527362T1 (de) Verbesserte expression zeigendemodifizierte xylanasen
FI20055198A0 (fi) Visualisointitekniikka biologista infomaatiota varten
BRPI0719007A2 (pt) Alelos do gene oxyr de bactérias corineformes
SE0701180L (sv) Räddningsflytväst
ITGE20050091A1 (it) Incubatrice
EP2058261A4 (en) LIFT DEVICE